Usual Adult Dose for Plaque Psoriasis

Recommended dose: 6 mg orally once a day

Comments:

• This drug may be taken with or without food.
• Evaluate patients for latent or active tuberculosis infection prior to treatment initiation.
• Avoid use with live vaccines.
• Use with other immunosuppressants is not recommended.

Use: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This drug is not recommended for use in combination with other potent immunosuppressants.

Renal Dose Adjustments

No dose adjustment recommended, including in patients with end-stage renal disease on dialysis.

Liver Dose Adjustments

Mild or Moderate Liver Dysfunction (Child-Pugh Class A or B): No adjustment recommended.
Severe Liver Dysfunction (Child-Pugh Class C): Use is not recommended.

Precautions

CONTRAINDICATIONS:

• Known hypersensitivity to this drug or any of the excipients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Report pregnancies to the Bristol-Myers Squibb Company's Adverse Event reporting line at 1-800-721-5072.

Dialysis

• No dose adjustments are recommended for patients on dialysis.
• This drug is not substantially cleared by dialysis from the systemic circulation.

Other Comments

Administration advice:

• Do not cut, crush, or chew tablets

Storage requirements:

• Store at 20C to 25C (68F to 77F).
• Excursions permitted between 15C and 30C (59F and 86F).

General:

• Ensure age appropriate immunizations are completed prior to therapy initiation, including prophylactic herpes zoster vaccination.
• Do not administer live vaccines during treatment.
• Treat cases of active or latent tuberculosis before starting therapy with this drug.

Monitoring:

• Periodically assess serum triglycerides to monitor for elevations.
• Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease.
• Monitor for signs and symptoms of infection during treatment, including viral reactivation and tuberculosis.

Patient advice:

• Read the FDA-approved patient labeling (Medication Guide).
• Report any symptoms of muscle pain or weakness.
• Promptly report signs and symptoms of infection to medical provider.
• Avoid live vaccinations while on therapy.
• Understand the potential risks related to treatment with janus kinase inhibitors.
• Advice patients to report their pregnancy to the Bristol-Myers Squibb Company's Adverse Event reporting line at 1-800-721-5072.

Frequently asked questions

• Sotyktu vs Otezla: How do they compare?
• How long can I take Sotyktu for?
• How is Sotyktu given / administered?